What is RenalSense?
RenalSense is a privately-held company specializing in the development of cutting-edge medical devices for continuous, automatic monitoring of renal function. Its flagship product, Clarity RMS, is designed to provide real-time urine flow data, thereby enhancing patient care and optimizing economic efficiencies within Intensive Care Units (ICUs). The company's strategic focus extends to next-generation products aimed at delivering additional real-time parameters and expanded diagnostic capabilities, further refining critical care management in both ICU and peri-operative environments.
How much funding has RenalSense raised?
RenalSense has raised a total of $14M across 1 funding round:
Series A
$14M
Series A (2021): $14M with participation from BlueRed Partners
Key Investors in RenalSense
BlueRed Partners
BlueRed Partners is an investment fund based in Singapore that concentrates on disruptive, early, and growth-stage technology companies originating from Israel, with a strategic focus on Asian markets. They aim to foster growth and development by leveraging innovative technologies.
What's next for RenalSense?
The recent major strategic investment signals a pivotal growth phase for RenalSense, likely enabling the company to accelerate product development, scale manufacturing, and expand its market reach. This capital infusion is expected to support the advancement of its next-generation diagnostic tools, further solidifying its position in the critical care technology market. The company's trajectory suggests a strong emphasis on innovation and market penetration within the high-acuity healthcare sector.
See full RenalSense company page
